Study | Exclusion reasons | Remarks | Reference(s) | ||
---|---|---|---|---|---|
Kawasuji, 2022 | - | no control group |
Kawasuji H et al. medrxiv;2022.02.23.22271433v1 10.1101/2022.02.23.22271433 |
||
Falsey, 0 | - | no control group |
Falsey AR et al. New England Journal of Medicine 10.1056/NEJMc2113468 |
||
BioNTech phase 2 (Walsh), 2020 | randomized controlled trial | no clinically relevant endpoint | phase 1-2 ; dose-escalation : 13 groups of 15 participants | ||
Pfizer 16-25 years phase 3, 0 | randomized controlled trial | other | very preliminary results from a press release |